Viva Biotech Holdings (FRA:VB0)
Germany · Delayed Price · Currency is EUR 0.2000
-0.0080 (-3.85%)
At close: Jan 20, 2026
Viva Biotech Holdings Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,837 | 1,987 | 2,156 | 2,380 | 2,104 | 696.96 | |
Revenue Growth (YoY) | -7.95% | -7.84% | -9.41% | 13.10% | 201.89% | 115.74% |
Cost of Revenue | 1,149 | 1,299 | 1,417 | 1,564 | 1,453 | 392.09 |
Gross Profit | 687.68 | 687.4 | 738.43 | 815.68 | 650.98 | 304.87 |
Selling, General & Admin | 373.07 | 364.12 | 409.66 | 404.45 | 320.29 | 123.26 |
Research & Development | 85.49 | 87.99 | 127.97 | 135.84 | 92.38 | 66.04 |
Other Operating Expenses | - | - | - | 3.37 | - | 3.03 |
Operating Expenses | 459.07 | 457.73 | 545.75 | 549.7 | 414.08 | 192.33 |
Operating Income | 228.61 | 229.67 | 192.68 | 265.98 | 236.9 | 112.54 |
Interest Expense | -41.06 | -53.89 | -176.58 | -184.67 | -183.11 | -62.13 |
Interest & Investment Income | 20.92 | 20.5 | 27.38 | 21.61 | 26.58 | 16.71 |
Earnings From Equity Investments | -0.51 | -0.1 | - | - | - | -0.49 |
Currency Exchange Gain (Loss) | 12.29 | 16.18 | -51.01 | -146.39 | 31.41 | - |
Other Non Operating Income (Expenses) | 22.89 | 32.74 | 210.93 | -4.33 | 188.05 | -542.14 |
EBT Excluding Unusual Items | 243.13 | 245.1 | 203.39 | -47.81 | 299.83 | -475.51 |
Gain (Loss) on Sale of Investments | 79.26 | 91.12 | -11.68 | -364.18 | 55.16 | 113.24 |
Gain (Loss) on Sale of Assets | -1.91 | -1.91 | 0.28 | -1.9 | -5.2 | 1.61 |
Asset Writedown | -38.61 | -38.61 | -25.19 | -6.57 | -2.1 | - |
Other Unusual Items | - | - | -222.76 | -38.7 | - | 4.45 |
Pretax Income | 281.88 | 295.71 | -55.95 | -459.17 | 347.7 | -356.21 |
Income Tax Expense | 55.5 | 73.72 | 43.84 | 45.06 | 47.14 | 22.66 |
Earnings From Continuing Operations | 226.39 | 221.99 | -99.79 | -504.22 | 300.56 | -378.87 |
Minority Interest in Earnings | -54.1 | -54.69 | -16.32 | -24.26 | -13.01 | -8.01 |
Net Income | 172.29 | 167.29 | -116.11 | -528.48 | 287.55 | -386.88 |
Net Income to Common | 172.29 | 167.29 | -116.11 | -528.48 | 287.55 | -386.88 |
Shares Outstanding (Basic) | 2,121 | 2,137 | 1,940 | 1,915 | 1,912 | 1,572 |
Shares Outstanding (Diluted) | 3,052 | 2,868 | 2,029 | 1,915 | 1,971 | 1,572 |
Shares Change (YoY) | 48.61% | 41.39% | 5.91% | -2.81% | 25.41% | 5.83% |
EPS (Basic) | 0.08 | 0.08 | -0.06 | -0.28 | 0.15 | -0.25 |
EPS (Diluted) | 0.06 | 0.06 | -0.14 | -0.28 | 0.08 | -0.25 |
Free Cash Flow | 214.34 | 183.32 | 195.73 | 136.72 | -487.35 | -549.44 |
Free Cash Flow Per Share | 0.07 | 0.06 | 0.10 | 0.07 | -0.25 | -0.35 |
Dividend Per Share | - | - | - | - | - | 0.023 |
Dividend Growth | - | - | - | - | - | 29.28% |
Gross Margin | 37.44% | 34.60% | 34.26% | 34.28% | 30.94% | 43.74% |
Operating Margin | 12.45% | 11.56% | 8.94% | 11.18% | 11.26% | 16.15% |
Profit Margin | 9.38% | 8.42% | -5.39% | -22.21% | 13.67% | -55.51% |
Free Cash Flow Margin | 11.67% | 9.23% | 9.08% | 5.75% | -23.16% | -78.83% |
EBITDA | 431.96 | 432.78 | 391.01 | 436.35 | 369.94 | 164.35 |
EBITDA Margin | 23.52% | 21.78% | 18.14% | 18.34% | 17.58% | 23.58% |
D&A For EBITDA | 203.35 | 203.11 | 198.33 | 170.37 | 133.04 | 51.81 |
EBIT | 228.61 | 229.67 | 192.68 | 265.98 | 236.9 | 112.54 |
EBIT Margin | 12.45% | 11.56% | 8.94% | 11.18% | 11.26% | 16.15% |
Effective Tax Rate | 19.69% | 24.93% | - | - | 13.56% | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.